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Summary
Background The increase in the worldwide incidence of endometrial cancer relates to rising obesity, falling fertility, and 
the ageing of the population. Transvaginal ultrasound (TVS) is a possible screening test, but there have been no large-
scale studies. We report the performance of TVS screening in a large cohort.
Methods We did a nested case-control study of postmenopausal women who underwent TVS in the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) following recruitment between April 17, 2001, and 
Sept 29, 2005. Endometrial thickness and endometrial abnormalities were recorded, and follow-up, through national 
registries and a postal questionnaire, documented the diagnosis of endometrial cancer. Our primary outcome measure 
was endometrial cancer and atypical endometrial hyperplasia (AEH). Performance characteristics of endometrial 
thickness and abnormalities for detection of endometrial cancer within 1 year of TVS were calculated. Epidemiological 
variables were used to develop a logistic regression model and assess a screening strategy for women at higher risk. 
Our study is registered with ClinicalTrials.gov, number NCT00058032, and with the International Standard Randomised 
Controlled Trial register, number ISRCTN22488978.
Findings 48 230 women underwent TVS in the UKCTOCS prevalence screen. 9078 women were ineligible because they 
had undergone a hysterectomy and 2271 because their endometrial thickness had not been recorded; however, 157 of 
these women had an endometrial abnormality on TVS and were included in the analysis. Median follow-up was 5·11 years 
(IQR 4·05–5·95). 136 women with endometrial cancer or AEH within 1 year of TVS were included in our primary 
analysis. The optimum endometrial thickness cutoﬀ  for endometrial cancer or AEH was 5·15 mm, with sensitivity 
of 80·5% (95% CI 72·7–86·8) and speciﬁ city of 86·2% (85·8–86·6). Sensitivity and speciﬁ city at a 5 mm or greater cutoﬀ  
were 80·5% (72·7–86·8) and 85·7% (85·4–86·2); for women with a 5 mm or greater cutoﬀ  plus endometrial 
abnormalities, the sensitivity and speciﬁ city were 85·3% (78·2–90·8) and 80·4% (80·0–80·8), respectively. For a cutoﬀ  
of 10 mm or greater, sensitivity and speciﬁ city were 54·1% (45·3–62·8) and 97·2% (97·0–97·4). When our analysis was 
restricted to the 96 women with endometrial cancer or AEH who reported no symptoms of postmenopausal bleeding at 
the UKCTOCS scan before diagnosis and had an endometrial thickness measurement available, a cutoﬀ  of 5 mm 
achieved a sensitivity of 77·1% (67·8–84·3) and speciﬁ city of 85·8% (85·7–85·9). The logistic regression model identiﬁ ed 
25% of the population as at high risk and 39·5% of endometrial cancer or AEH cases were identiﬁ ed within this high risk 
group. In this high-risk population, a cutoﬀ  at 6·75 mm achieved sensitivity of 84·3% (71·4–93·0) and speciﬁ city 
of 89·9% (89·3–90·5).
Interpretation Our ﬁ ndings show that TVS screening for endometrial cancer has good sensitivity in postmenopausal 
women. The burden of diagnostic procedures and false-positive results can be reduced by limiting screening to a 
higher-risk group. The role of population screening for endometrial cancer remains uncertain, but our ﬁ ndings are of 
immediate value in the management of increased endometrial thickness in postmenopausal women undergoing 
pelvic scans for reasons other than vaginal bleeding.
Funding Cancer Research UK, Medical Research Council, NHS Research and Development, and The Eve Appeal.
Introduction
Endometrial cancer is the most common gynaecological 
cancer in Europe, and has an increasing incidence in 
postmenopausal women in many northern and western 
European countries.1 In the UK, overall incidence of 
endometrial cancer increased from 13·5 per 100 000 in 1993 
to 17·9 per 100 000 in 2005.2 The increase in obesity3 and 
the fall in fertility rates suggest that incidence of 
endometrial cancer will continue to rise in postmenopausal 
women, and will become a substantial public health 
problem worldwide.4 This rise in incidence has implications 
for both primary prevention and screening.
Screening for endometrial cancer is only recommended 
in women with Lynch syndrome, a disorder that genetically 
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predisposes women to endometrial cancer with a lifetime 
risk of 40–60%.5,6 Recommended surveillance in this group 
includes annual transvaginal ultrasound (TVS) and 
endometrial biopsy from age 35 years.7 In the general 
population, there has been limited enthusiasm to explore 
the usefulness of screening for endometrial cancer8 
because patients have a good prognosis relative to other 
cancers. However, in view of the rising incidence of 
endometrial cancer,4 coupled with increasing life 
expectancy,9 there is now a need to revisit screening. 
Additional factors are mortality greater than 30% within 
10 years of diagnosis10 and a proven link between stage and 
survival raising the possibility of a mortality beneﬁ t from 
earlier detection.10 Of note, stage for stage, survival rates for 
endometrial cancer are similar to ovarian cancer—a cancer 
for which large-scale screening trials are underway.11,12
The techniques commonly used to assess the 
endometrium in symptomatic women are TVS and 
endometrial sampling. Few studies have been done to 
assess the merits of screening for detection of 
endometrial cancer in asymptomatic women. The largest 
study13 screened 1926 postmenopausal women from the 
general population with TVS. One case of endometrial 
cancer and four cases of atypical hyperplasia were 
detected. Other studies14–16 have included smaller 
populations, making it impossible to assess the 
sensitivity of screening, or to achieve conﬁ dent estimates 
of speciﬁ city or positive predictive value.
The opportunity to study the performance of TVS in a 
large cohort of postmenopausal women was provided by 
data from the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS).12,17 UKCTOCS is a 
prospective trial of ovarian cancer screening, one arm of 
which involved pelvic ultrasound during which endometrial 
thickness was measured and recorded. This provided the 
opportunity to establish the performance characteristics of 
endometrial thickness as a possible screening test for 
endometrial cancer. Documentation of endometrial 
characteristics during TVS screening in the trial, and 
follow-up for cancer outcomes, provided unique data. We 
report on the characteristics of endometrial cancer 
screening in postmenopausal women in the general 
population to inform on the potential of screening for 
endometrial cancer.
Methods
Participants
We did a nested case-control study within the UKCTOCS 
cohort with ultrasound ﬁ ndings recorded at yearly 
screening appointments as part of the ovarian cancer 
screening trial. Between April 17, 2001, and Sept 29, 2005, 
202 638 women were recruited to UKCTOCS from 
England, Wales, and Northern Ireland. The pre-identiﬁ ed 
Scottish centres dropped out because of logistical issues 
(lack of space, retirement of potential research leads, 
unwillingness of NHS Trust management to commit to a 
10-year trial, involvement in other ovarian cancer screening 
trials).17 Participants completed a recruitment question-
naire, which requested baseline data on lifestyle and 
reproductive factors, previous cancer history, and family 
history of breast or ovarian cancer.17 The focus of the 
recruitment questionnaire was on risk factors for ovarian 
cancer and the trial was not resourced to collect all variables 
related to endometrial cancer risk at the initial visit. 
50 639 participants were randomly assigned to yearly 
screening with TVS; 48 230 attended the initial prevalence 
screen and are included in our study.
All women assigned to screening with TVS who had 
undergone the prevalence screen were included as cases 
or controls. Cases were women with a conﬁ rmed diagnosis 
of endometrial cancer or atypical endometrial hyper-
plasia (AEH), complex endometrial hyperplasia (CEH), 
endometrial stromal sarcoma (ESS), or carcino sarcoma. 
The scan in the year before diagnosis was used for the 
analysis. When several scans had been done during this 
year, the scan closest to diagnosis was used. Controls were 
women with none of the above diagnoses during follow-
up. We used the initial prevalence scan for analysis. We 
excluded from our study all women assigned to screening 
with TVS who had undergone hysterectomy before random 
assignment in UKCTOCS or who had no endometrial 
thickness measurement or recorded endometrial 
abnormality on the relevant scan. All participants provided 
written consent for the use of data in secondary studies. 
Our study was covered by the ethical approval obtained for 
the main UKCTOCS (MREC reference 00/8/34, granted 
by North West MREC).
Procedures
TVS with Kretz/Medison SA9900 (Medison, Seoul, South 
Korea) ultrasound machines was done by experienced 
ultrasonographers at the 13 trial centres in the UK. All 
sonographers had, at a minimum, a diploma in medical 
ultrasound or similar qualiﬁ cation and experience in 
gynaecological ultrasound. All underwent induction 
training, which included scanning with the national lead 
sonographer or one of the members of the ultrasound 
subcommittee before scanning on the trial. During the 
course of the trial, they completed an accreditation 
programme and attended yearly ultrasound days.
The ultrasonographers were instructed to ask about and 
record symptoms of postmenopausal bleeding. We do not 
know how accurately postmenopausal bleeding was 
documented and there might have been a bias to better 
documentation in women who had an endometrial 
thickness above the level which prompted clinical referral 
(>5 mm) according to current guidelines. In all women 
who reported that they had experienced any irregular 
bleeding to the sonographer, data were recorded on the 
ultrasound form. During scanning, details of ovarian 
morphology and size were recorded. Furthermore, 
endometrial thickness and pathology were recorded 
routinely. Representative grey-scale images of each ovary 
and the uterus were archived at the coordinating centre.12
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At TVS, endometrial thickness was measured at its 
thickest point from the anterior to the posterior in the 
sagittal plane of the uterus. Callipers were placed 
perpendicular to the outer edge of the endometrium. If 
there was ﬂ uid in the endometrial cavity, the endometrial 
thickness was measured as above but with the inclusion 
of the cavity ﬂ uid and the double endometrial stripe, 
then the ﬂ uid diameter was subtracted at the same point. 
Measurements of endometrial thickness were done 
prospectively, but were not a criterion for intervention in 
the trial. In addition to measurements of endometrial 
thickness, details of any clinical ﬁ ndings were recorded. 
For the purposes of our study, thickened, irregular, 
cystic, heterogeneous, abnormal, or distended 
endometrium; ﬂ uid in the endometrial cavity; or polyp 
or other mass or lesion were included under the 
deﬁ nition of endometrial abnormality.
In clinical practice, asymptomatic women are not 
investigated. However, in the presence of postmenopausal 
bleeding, endometrial thickness greater than 4 mm is 
deemed abnormal and investigated further. In the absence 
of any deﬁ nitive data at the start of the trial, a pragmatic 
decision to recommend referral of asymptomatic women 
with an endometrial thickness greater than 10 mm was 
agreed on the basis of extensive discussion and 
consultation with clinicians. We emphasise that there was 
no systematic protocol-driven intervention based on 
endometrial thickness.
Trial guidelines for the management of endometrial 
thickness stated that all women with thickness greater 
than 5 mm should be questioned about bleeding. In the 
UK National Health Service, postmenopausal bleeding 
prompts a 2-week referral to assess for cancer, and all 
centres would have followed this, irrespective of 
measurements of endometrial thickness. Women with 
irregular bleeding were advised to see their family doctor 
so that they could be referred to a gynaecologist as part of 
standard clinical practice in the UK. Furthermore, the 
guideline recommended that asymptomatic women with 
thickness greater than 10 mm be considered for referral to 
a gynaecologist for further assessment. The guidance for 
asymptomatic women was the same in all of the 
collaborating centres. However, whether asymptomatic 
women were investigated further was at the discretion of 
the local investigator. Data on any diﬀ erences between the 
centres are not yet available.
All participants were followed up through a ﬂ agging 
study with the NHS Information Centre for Health and 
Social Care (formerly Oﬃ  ce of National Statistics) in 
England and Wales and via the Central Services Agency 
and Cancer Registry in Northern Ireland as appropriate. 
This provides regular notiﬁ cation of any cancer 
registrations or deaths in the cohort. For the purpose of 
this analysis, cancer registration data were obtained from 
the agencies on Feb 9, 2009. Women also directly 
informed the trial centre of a cancer when diagnosed or 
when they were sent an appointment for the next yearly 
screen. Furthermore, women who had been on the trial 
for 3·5 years after random assignment were sent follow-
up questionnaires.
In all women where diagnoses of endometrial cancer, 
AEH, CEH, ESS, or carcinosarcoma were notiﬁ ed on 
Women without EC
N=36 731
Women with EC/AEH
N=136
p value
Age at random assignment (years) 60·4; 56·0–65·9 (36 731) 61·6; 56·8–66·5 (136) 0·15
Time since last period at random assignment (years) 9·6; 4·2–15·9 (36 730) 8·4; 4·2–15·3 (136) 0·51
Duration of HRT use in those who were on HRT at random assignment (years) 7·4; 4·2–10·9 (6211) 6·9; 4·6–10·6 (22) 0·96
Duration of OCP use (years) 5·0; 2·0–10·0 (21 967) 5·0; 2·0–10·0 (65) 0·55
Number of miscarriages (pregnancies <6 months) 0; 0–1 (36 218) 0; 0–1 (134) 0·18
Number of children (pregnancies >6 months) 2; 2–3 (36 632) 2; 1–3 (135) 0·0073
Height (cm) 162·6; 157·5–165·1 (36 644) 162·6; 157·5–167·6 (136) 0·14
Weight (kg) 66·7; 60·3–76·2 (36 604) 72·8; 63·5–83·5 (134) <0·0001
Ethnic origin 0·81
White 35 459 (96·5%) 134 (98·5%) ··
Black 450 (1·2%) 1 (0·7%) ··
Asian 337 (0·9%) 0 ··
Other 311 (0·8%) 0 ··
Missing 174 (0·5%) 1 (0·7%) ··
Use of OCP 22 280 (60·7%) 66 (48·5%) 0·006
Use of HRT at recruitment 6211 (16·9%) 22 (16·2%) 0·99
Personal history of cancer* 2072 (5·6%) 15 (11·0%) 0·014
Personal history of breast cancer 1409 (3·8%) 9 (6·6%) 0·11
Data are median; IQR (n) or n (%). EC=endometrial cancer. AEH=atypical endometrial hyperplasia. HRT=hormone replacement therapy. OCP=oral contraceptive pill. *Includes 
those with personal history of breast cancer.
Table 1: Baseline characteristics of UKCTOCS participants who underwent the ﬁ rst yearly scan
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follow-up, copies of operative notes, histopathology reports, 
cytology reports, discharge summaries, multidisciplinary 
team meeting notes, and other correspondence were 
obtained. The ﬁ nal diagnosis—which included the primary 
site, stage, and grade of any cancer—was made on review 
of the medical notes by an independent gynaecological 
oncologist (RM).
Our primary outcome measure was endometrial cancer 
and AEH. AEH was included because 40% of cases of AEH 
might have concurrent EC,18 there is limited concordance 
between pathologists on the diagnosis of AEH or 
endometrial cancer,19 and AEH is a precancerous state with 
greater than 25% of patients progressing to endometrial 
cancer (estimates range from 25% to 82%).20–25 ESS, 
carcinosarcoma, and CEH were also analysed separately.
Statistical analysis
The distribution of endometrial thickness was compared 
in women who did and did not develop endometrial 
cancer or AEH. These data were used to construct a 
receiver operator characteristic (ROC) curve to assess the 
speciﬁ city and sensitivity of various thickness cutoﬀ s for 
detecting endometrial cancer or AEH. A further ROC 
curve was constructed with both thickness and any 
recorded endometrial abnormality. The latter analysis 
included women with either endometrial thickness, 
endometrial abnormality, or both recorded. A multivariate 
logistic-regression analysis was done that combined 
thickness with the baseline characteristics of the study 
participants to develop an algorithm incorporating 
epidemiological variables that would identify a high-risk 
group who might beneﬁ t from a targeted approach to 
screening. Further ROC curves were constructed to assess 
the speciﬁ city and sensitivity of various endometrial 
thickness cutoﬀ s for detecting endometrial cancer or 
AEH in the diﬀ erent risk groups.
Further analyses assessed the sensitivity and speciﬁ city 
proﬁ le of endometrial thickness for the detection of 
endometrial cancers, either alone or combined with CEH, 
ESS, or carcinosarcoma, with a scan done within a year of 
diagnosis. Subgroup analysis was by presence or absence 
of postmenopausal bleeding. Since there was no 
systematic protocol-driven intervention based on 
endometrial thickness, we did not analyse the data by 
stage of endometrial cancer.
To explore the possibility of reﬁ ning screening in a 
higher-risk group, the baseline characteristics recorded 
at recruitment for women diagnosed with endometrial 
cancer in the control and multimodal groups of the trial 
were modelled as epidemiological risk factors for 
endometrial cancer with forward stepwise logistic 
regression. The signiﬁ cant factors and their parameter 
estimates were retained for a high-risk logistic-
regression model. These factors were weight; age at 
menarche; use of the oral contraceptive pill; personal 
history of breast, ovarian, lung, bowel, or other cancer; 
age at scan; and any pregnancy of longer than 6 months 
(webappendix p 1). Data on the relevant variables for the 
ultrasound group were then inserted into the derived 
high-risk model and a prior risk probability of 
endometrial cancer was calculated solely on the basis 
of epidemiological data. These groups were based on 
the cutoﬀ s of the ordered prior risk probabilities: the 
highest risk (ﬁ rst) quartile, the second quartile, the third 
quartile, and those at lowest risk (fourth quartile). 
Relative risks (RRs) were used because the prevalence of 
endometrial cancer was virtually unchanged from the 
prevalence of endometrial cancer in the trial population 
for those without hysterectomy.
Ovarian volume was assessed as another variable to 
identify women at higher risk of endometrial cancer or 
AEH by comparing measurements of those who developed 
endometrial cancer or AEH and those who had not.
The relative risk of endometrial cancer or AEH in 
women with thickness measurements of 5 mm or greater 
or 10 mm or greater were calculated to show the 
endometrial thickness cutoﬀ s suggested by the UKCTOCS 
guidelines. Data were analysed with the PASW Statistics 18 
package and Stata 11.0. Our study is registered with 
ClinicalTrials.gov, number NCT00058032, and with the 
International Standard Randomised Controlled Trial 
register, number ISRCTN22488978.
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Figure 1: Receiver operator curves for detection of endometrial cancer and atypical endometrial hyperplasia
Endometrial thickness measurements alone (A) and a combination of endometrial thickness measurements and 
endometrial abnormality (B). Diagonal segments are produced by ties.
Women without EC or AEH
n=36 731
Women with EC or AEH
n=133
Relative risk (95% CI)
<5 mm 30 664 (83·5%) 26 (19·5%) 1
≥5 to 10 mm 4878 (13·3%) 33 (24·8%) 7·93 (4·77–13·18)
≥10 to 20 mm 1116 (3·0%) 59 (44·4%) 59·27 (37·67–93·36)
≥20 mm 73 (0·2%) 15 (11·3%) 201·2 (110·64–360·63)
Mean (SD) 3·46 mm (2·59) 11·53 mm (7·81) ··
Median (IQR) 2·9 mm (2·0–4·0) 11·0 mm (6·0–14·5) ··
Data are n (%) unless otherwise indicated. EC=endometrial cancer. AEH=atypical endometrial hyperplasia.
Table 2: Distribution of endometrial thickness measurements in women with or without endometrial 
cancer or atypical endometrial hyperplasia
See Online for webappendix
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Role of the funding source
The sponsor of the study and the funding sources had no 
role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication. AG-M, MB, RM, AR, and UM also had access 
to the raw data.
Results
Table 1 shows the baseline characteristics of the women 
with and without endometrial cancer or AEH. The 
inclusion criteria and details of the UKCTOCS trial have 
been described in detail elsewhere.12,17 50 639 study 
participants were randomly assigned to the ultrasound 
arm of UKCTOCS. 48 230 completed the ﬁ rst yearly scan 
on the trial (prevalence screen). Of these women, 
11 349 were ineligible because 9078 women had 
undergone a hysterectomy, and 2271 did not have 
endometrial thickness recorded on their scan report. 
157 of the 2271 women had an endometrial abnormality 
reported in absence of endometrial thickness 
measurement and were included in our analysis. The 
resulting group of 37 038 women were included in our 
study (web appendix pp 5–6).
Median follow-up from the scan to cancer registration 
update was 5·11 years (IQR 4·05–5·95). Since 
information on cancers can take up to 3 years to be 
recorded on the national cancer registries, we explored 
other sources of follow-up data in detail in the 985 women 
for whom the time from scan to cancer registry follow-
up on Feb 9, 2009, was less than 3 years. In this cohort, 
we had additional conﬁ rmation of endometrial cancer 
status in 849 women because they had attended further 
screening and in 66 of the remaining women through 
returned follow-up questionnaires. In 70 of 37 038 women, 
the only source of information on endometrial cancer 
status was cancer registry follow-up of less than 3 years 
from the date of scan.
The cohort of 37 038 women includes 125 women who 
developed endometrial cancer after random assignment 
(100 endometrioid [80%], six papillary serous [5%], two 
clear cell [2%], three mixed subtype [2%], one 
mucoid [1%], and 13 endometrial carcinoma without 
speciﬁ cation of histological subtype [10%]), six with ESS, 
six with carcinosarcomas or mixed Müllerian tumours, 
11 with AEH, and two with CEH. 133 of the 136 women 
with endometrial cancer or AEH had endometrial 
thickness measurements recorded and three had 
endometrial abnormalities. 96 of the 125 women who 
Measure Number 
of cases
Area under 
curve 
(95% CI)
>5 mm ET cutoﬀ >10 mm ET cutoﬀ Optimum cutoﬀ 
n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
Cutoﬀ  
(mm)
n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
EC+AEH ET 133 0·872
(0·834–
0·912)
107 0·805
(0·727–
0·868)
31 478 0·857
(0·854–
0·862)
72 0·541
(0·453–
0·628)
35 703 0·972
(0·970–
0·974)
5·15 107 0·805
(0·727–
0·868)
31 662 0·862
(0·858–
0·866)
EC+AEH ET+EA 136 0·844
(0·811–
0·878)
116 0·853
(0·782–
0·908)
29 657 0·804
(0·800–
0·808)
89 0·654
(0·568–
0·734)
33  051 0·896
(0·893–
0·899)
5·80 113 0·831
(0·757–
0·890)
30 506 0·827
(0·823–
0·831)
EC+AEH 
(HRT only)
ET 22 0·901
(0·842–
0·959)
19 0·864
(0·651–
0·971)
4676 0·753
(0·742–
0·764)
11 0·500
(0·282–
0·718)
6030 0·971
(0·967–
0·975)
6·85 17 0·773
(0·546–
0·922)
5459 0·879
(0·871–
0·887)
EC+AEH 
(HRT only)
ET+EA 23 0·864
(0·808–
0·920)
20 0·870
(0·664–
0·972)
4454 0·715
(0·704–
0·726)
12 0·522
(0·306–
0·732)
5682 0·912
(0·905–
0·919)
6·85 18 0·783
(0·563–
0·925)
5177 0·831
(0·822–
0·840)
EC+AEH 
(non-HRT only)
ET 111 0·868
(0·823–
0·913)
88 0·793
(0·705–
0·864)
26 889 0·881
(0·877–
0·885)
61 0·550
(0·452–
0·644)
29 666 0·972
(0·970–
0·974)
4·55 92 0·829
(0·746–
0·894)
25 577 0·838
(0·834–
0·842)
EC+AEH 
(non-HRT only)
ET+EA 113 0·839
(0·801–
0·877)
96 0·850
(0·770–
0·910)
25 231 0·823
(0·819–
0·827)
77 0·681
(0·587–
0·766)
27 377 0·893
(0·889–
0·896)
5·15 96 0·850
(0·770–
0·910)
25 323 0·826
(0·822–
0·830)
EC+AEH+CEH+ESS 
or carcinosarcoma
ET 147 0·873
(0·836–
0·910)
117 0·796
(0·722–
0·858)
31 515 0·858
(0·854–
0·862)
80 0·544
(0·460–
0·626)
35 703 0·972
(0·970–
0·974)
5·15 117 0·796
(0·722–
0·858)
31 662 0·862
(0·858–
0·866)
EC+AEH+CEH+ESS 
or carcinosarcoma
ET+EA 150 0·844
(0·812–
0·876)
127 0·847
(0·779–
0·900)
29 657 0·804
(0·800–
0·808)
99 0·660
(0·578–
0·735)
33 051 0·896
(0·893–
0·899)
5·15 127 0·847
(0·779–
0·900)
29 805 0·808
(0·804–
0·812)
The analysis was done separately for endometrial thickness (ET) alone (no women who had no ET measurements were included) and for ET and endometrial abnormality (EA). In the latter analysis, the 
157 women in the overall cohort who had no ET recorded, but had an EA recorded, were included. In ET+EA measure all EA cases count as maximum ET—ie, always positive. n=number. EC=endometrial cancer. 
AEH=atypical hyperplasia. HRT=hormone replacement therapy. CEH=complex hyperplasia. ESS=endometrial stromal sarcoma.
Table 3: Performance characteristics of endometrial thickness as a screening tool for endometrial cancer with and without endometrial abnormality
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developed endometrial cancer after random assignment 
were stage 1, 11 were stage 2, nine were stage 3, and one 
was stage 4. Data on stage were not available for eight 
women. Overall, 112 of the 136 women with endometrial 
cancer or AEH were asymptomatic and 24 were 
symptomatic at the last UKCTOCS scan before diagnosis 
(of 99 women with endometrial cancer or AEH who 
reported no postmenopausal bleeding, 96 had 
endometrial thickness measurements available).
The remainder of the cohort is 36 888 controls, who are 
women without a diagnosis of endometrial cancer or 
AEH within 1 year of their last UKCTOCS scan. The 
control group includes six women who had either a 
leiomyosarcoma or breast cancer that was metastatic to 
the endometrium and 23 women who had endometrial 
cancer or AEH diagnosed more than 1 year after the last 
UKCTOCS scan. 36 731 of the women in the control group 
had endometrial thickness measurements and the 
remaining 157 had endometrial abnormalities recorded. 
In 2271 (5·5%) of 41 561 women with an intact uterus, 
data on endometrial thickness were missing. The 
5% missing data rate is in keeping with what was 
anticipated for a study of this type and size.
Weight, age, and personal history of cancer were 
associated with an increased risk of endometrial cancer or 
AEH, although oral contraceptive pill, age at menarche, 
and parity were associated with a decreased risk 
(webappendix p 1).
Table 2 shows the distribution of endometrial thickness 
measurements in the 36 731 women who did not have a 
diagnosis of endometrial cancer or AEH. Most of the 
women had an endometrial thickness of less than 5 mm. 
In the 133 women with a diagnosis of endometrial cancer 
or AEH who had endometrial thickness recorded, 
107 (81%) had an endometrial thickness of 5 mm or 
greater. There was a signiﬁ cant diﬀ erence between 
endometrial thickness in women with and without 
endometrial cancer or AEH (p<0·0001). The optimum 
cutoﬀ  for endometrial thickness was 5·15 mm with a RR 
of 25·2 (95% CI 16·5–38·5).
The webappendix (p 2) shows the distribution of 
endometrial thickness measurements according to the 
use of hormone replacement therapy (HRT) in the 
overall cohort. The median endometrial thickness in 
women in the whole cohort who did not use HRT was 
2·7 mm (IQR 2·0–3·95) versus 3·6 mm (2·5–5·1) in 
women that did and these results were similar in the 
subgroup of women without endometrial cancer or AEH 
(p<0·0001). By contrast, the median thickness was 
11·0 mm (5·9–14·8 without HRT; 7·0–14·5 with HRT) 
in women with endometrial cancer or AEH, irrespective 
of the use of HRT.
1406 women reported breast cancer diagnosis before 
entry into the trial. These women were more likely to 
have an endometrial thickness of 5 mm or greater to less 
than 10 mm (RR 1·91; 95% CI 1·68–2·18), 10 mm or 
greater to less than 20 mm (4·50; 3·85–5·25), and 20 mm 
or greater (11·01; 8·04–14·47) than women with no 
history of breast cancer (webappendix, p 3). Of the 
women with no history of breast cancer, 29 757 (83·9%) of 
35 460 had an endometrial thickness of less than 5 mm 
compared with 940 (66·9%) of 1406 women with history 
of breast cancer—the median endometrial thickness was 
2·9 mm versus 3·6 mm (p<0·0001; webappendix p 3). 
A large proportion of this measurement in women with 
breast cancer was probably related to tamoxifen use, but 
treatment data were not systematically captured as part 
of the trial.
We did an analysis of endometrial thickness by 
screening centre in the women who did not develop 
endometrial cancer. The median endometrial thickness 
was 2·9 mm. The median thickness varied from 2·1 mm 
Overall Positive for bleeding Negative for bleeding
Number % (95% CI) Number % (95% CI) Number % (95% CI)
5 mm cutoﬀ 
>5 mm 107 .. 33 .. 74 ..
≤5 mm 31 464 .. 54 .. 31 410 ..
Sensitivity .. 80·5% (72·7–86·8) .. 89·2% (76·9–95·6) .. 77·1% (67·8–84·3)
Speciﬁ city .. 85·7% (85·4–86·2) .. 42·2% (38·6–44·0) .. 85·8% (85·7–85·9)
Positive predictive value .. 2·0% (1·8–2·1) .. 30·8% (26·6–33·1) .. 1·4% (1·2–1·5)
Negative predictive value .. 99·9% (99·9–99·9) .. 93·1% (85·2–97·2) .. 99·9% (99·9–100)
10 mm cutoﬀ 
>10 mm 72 .. 24 .. 48 ..
≤10 mm 35 746 .. 99 .. 35 586 ..
Sensitivity .. 54·1% (45·3–62·8) .. 64·9% (51·0–76·7) .. 50·0% (40·3–59·7)
Speciﬁ city .. 97·2% (97·0–97·4) .. 77·3% (73·4–80·8) .. 97·2% (97·1–97·3)
Positive predictive value .. 6·4% (5·4–7·4) .. 45·3% (35·7–53·5) .. 4·5% (3·6–5·4)
Negative predictive value .. 99·8% (99·8–99·9) .. 88·4% (83·8–92·3) .. 99·9% (99·8–99·9)
Table 4: Performance characteristics of endometrial thickness as a screening tool for endometrial cancer in women with and without postmenopausal 
bleeding
Articles
44 www.thelancet.com/oncology   Vol 12   January 2011
to 3·4 mm across the regional centres. All but three 
centres had a median thickness within 0·3 mm of the 
overall median thickness. When dichotomised as 
endometrial thickness less than 5 mm and 5 mm or 
greater, the proportion of measurements greater than 5 
mm per centre varied from 10·4% to 22·4% (overall 
proportion 16·8%; median centre proportion 16·6%, IQR 
14·7–19·8).
To assess the sensitivity and speciﬁ city proﬁ le for 
detection of endometrial cancer or AEH, a ROC curve was 
constructed with cutoﬀ  points for endometrial thickness 
with or without data for endometrial abnormalities 
(ﬁ gure 1, webappendix p 4). Table 3 shows the sensitivities 
and speciﬁ cities at 5 mm and 10 mm cutoﬀ s and shows 
the optimum cutoﬀ s. A separate ROC curve was 
constructed incorporating endometrial abnormality 
ﬁ ndings in addition to thickness measurements (ﬁ gure 1, 
table 3). Use of endometrial abnormality ﬁ ndings and 
thickness measurements at a cutoﬀ  of 5 mm or greater 
increased sensitivity but decreased speciﬁ city. The same 
eﬀ ect was noted at a cutoﬀ  of 10 mm or greater (ﬁ gure 1, 
table 3). In asymptomatic women the optimum endometrial 
thickness cutoﬀ  was 4·45 mm.
Table 3 shows analyses of combined endometrial 
cancer, AEH, CEH, and sarcomas. Our subgroup analyses 
that included endometrial cancer and AEH or a 
combination of endometrial cancer, AEH, CEH, and ESS 
or carcinosarcoma showed similar levels of sensitivity 
and speciﬁ city.
Given the diﬀ erence noted in endometrial thickness 
distribution in users of HRT and non-users, the optimum 
cutoﬀ  in HRT users was as expected higher (6·85 mm) 
than non-users (4·55 mm; table 3).
At the UKCTOCS scan, postmenopausal bleeding was 
recorded in 165 women (37 cases and 128 controls). Table 4 
shows the performance characteristics for women with 
and without postmenopausal bleeding.
The relation between ovarian volume and endometrial 
cancer or AEH was assessed and no statistically signiﬁ cant 
correlation was identiﬁ ed (p=0·956; data not shown).
We explored the possibility of optimising approaches 
to endometrial cancer screening by incorporating 
epidemiological information provided in the recruitment 
questionnaire. Logistic regression showed that decreased 
endometrial cancer or AEH risk was associated with the 
use of the oral contraceptive pill, age at menarche, and 
pregnancies longer than 6 months, while increased risk 
was associated with rising weight, increasing age, and 
personal history of breast and other cancer (multivariate 
and univariate analyses are shown in webappendix p 1). 
On the basis of the logistic regression model, the 
population could be divided into quartiles with RRs for 
endometrial cancer compared with the entire population 
of 1·98 (1·39–2·80) for the ﬁ rst quartile, 1·07 (0·73–1·58) 
for the second, 0·76 (0·49–1·16) for the third, and 0·49 
(0·30–0·79) for the fourth (table 5). The population in 
the highest quartile of risk (ﬁ rst quartile) included 39·5% 
of women with endometrial cancer or AEH; in this 
population an optimum endometrial thickness cutoﬀ  at 
6·75 mm achieved a sensitivity of 84·3% and speciﬁ city 
of 89·9% (ﬁ gure 2, table 5).
We also assessed the number of further interventions 
that would be predicted if endometrial thickness 
measurements were used as a screen for endometrial 
cancer or AEH (table 6). If the entire population were 
screened, an endometrial thickness cutoﬀ  of 5 mm or 
greater would result in 58 women undergoing further 
investigation per case of endometrial cancer or AEH 
detected for the diagnosis of 80·5% (107 of 133) of cancers. 
A cutoﬀ  of 10 mm or greater, would lead to 17 women 
being investigated to detect each case of endometrial 
cancer (55·6% [74 of 133 cancers diagnosed]). The number 
of investigations per case of endometrial cancer or AEH 
for the optimum cutoﬀ  of 5·15 mm was 47·7 (data not 
shown). If the proportion of the population screened was 
reduced by the use of our logistic regression model to 
limit screening to the top quartile risk group, 22 women 
would have to undergo investigation per endometrial 
cancer detected for the detection of 43 (32·3%) cases in 
the entire population.
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Figure 2: Receiver operator curve for endometrial thickness measurements for detection of endometrial 
cancer in the high-risk group
First quartile (A), second quartile (B), third quartile (C), and fourth quartile (D). Diagonal segments are 
produced by ties.
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The Prostate, Lung, Colorectal, and Ovarian (PLCO) 
cancer screening trial currently underway in the USA,11 has 
recruited 78 237 postmenopausal women of whom 34 261 
will undergo screening with both cancer antigen 125 for 
5 years and TVS for 3 years. The ultrasound ﬁ ndings have 
shown that ovarian volume greater than 3 cm³ could be 
used as a variable to identify women at higher risk of 
endometrial cancer or AEH. When we assessed this in our 
cohort, we found that for the left ovary, the use of the 
suggested cutoﬀ  of 3 cm³, the p value was 0·063 and for 
the right ovary p was 0·218.
Discussion
Ultrasound imaging of the endometrium has long 
been thought a possible screening test for endometrial 
cancer. However, there has been a dearth of data 
about the performance of potential tests and the largest 
study involved fewer than 2000 women and only 
one endometrial cancer was diagnosed.13 The UKCTOCS 
protocol enabled us to assess the performance of 
TVS in screening for endometrial cancer in 
37 038 postmenopausal women. With an endometrial 
thickness cutoﬀ  of 5 mm, sensitivity was 80·5% and 
speciﬁ city was 85·7% for endometrial cancer or AEH. 
An increased cutoﬀ  of 10 mm or greater resulted in a 
reduced sensitivity and increased speciﬁ city (table 3). 
When the analysis was restricted to women who 
reported no symptoms of postmenopausal bleeding at 
the scan and had an endometrial thickness measurement 
available, a cutoﬀ  of 5 mm achieved a sensitivity 
of 77·1% and speciﬁ city of 85·8% (table 4). Although 
the role of population screening for endometrial cancer 
remains uncertain, the ﬁ ndings are of immediate value 
in the management of increased endometrial thickness 
in postmenopausal women undergoing pelvic scans for 
reasons other than vaginal bleeding.
Our ﬁ ndings conﬁ rm the strong correlation between 
TVS ﬁ ndings and subsequent diagnosis of endometrial 
cancer, as shown by the RRs (table 2). The RR for a 
cutoﬀ  of 5·15 mm was 25·2. The optimum cutoﬀ  in the 
high-risk group was 6·75 mm, with an RR of 43·73. 
This correlation was shown by the levels of sensitivity 
ET cut-oﬀ  (mm) Number of cases 
of EA/AEH with 
positive result
Proportion of 
EC cases 
detected
Number of 
women with 
positive result 
Risk of EC/AEH Relative risk of EC/AEH 
(95% CI)
Number of 
investigations per 
case detected
Whole population screened >0 133 100·00% 36 864 0·36% 1·00 277
Whole population screened ≥5 107 80·45% 6174 1·73% 20·47 (13·39–31·30) 58
Whole population screened ≥10 74 55·64% 1263 5·86% 35·37 (25·84–49·50) 17
Whole population screened ≥20 15 11·28% 88 17·05% 53·15 (32·11–85·00) 6
First quartile (highest risk) screened >6·75 43 32·33% 954 4·51% 43·73 (20·99–90·32)* 22
Second quartile screened >4·85 28 21·05% 1535 1·82% 22·63 (9·64–53·19)* 55
Third quartile screened >4·65 17 12·78% 1665 1·02% 8·38 (3·82–18·40)* 98
Fourth quartile (lowest risk) screened >5·75 17 12·78% 938 1·81% 145·88 (24·81–860·25)* 55
*Relative risk within the risk quartile. EC=endometrial cancer. AEH=atypical endometrial hyperplasia. ET=endometrial thickness.
Table 6: Number of further interventions predicted if endometrial thickness measurements were used to screen for EC/AEH
Number 
of cases/
controls
Proportion 
of cases 
included
RR of EC 
(95% CI)
Area under 
curve (95% CI)
>5 mm ET cutoﬀ >10 mm ET cutoﬀ Optimum cutoﬀ 
n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
Cutoﬀ n Sensitivity 
(95% CI)
n Speciﬁ city 
(95% CI)
First 
quartile
51/9015 39·5% 1·98 
(1·39–
2·80)
0·902 
(0·848–
0·957)
44 0·863 
(0·737–
0·943)
7546 0·837 
(0·829–
0·845)
32 0·627 
(0·481–
0·759)
8654 0·960 
(0·956–
0·964)
6·75 mm 43 0·843 
(0·714–
0·930)
8104 0·899 
(0·893–
0·905)
Second 
quartile
34/9081 26·4% 1·07 
(0·73–
1·58)
0·878 
(0·808–
0·948)
27 0·794 
(0·621–
0·913)
7846 0·864 
(0·857–
0·871)
16 0·471 
(0·298–
0·649)
8863 0·976 
(0·973–
0·979)
4·85 mm 28 0·824 
(0·655–
0·932)
7574 0·834 
(0·826–
0·842)
Third 
quartile
26/9104 20·2% 0·76 
(0·49–
1·16)
0·744 
(0·623–
0·865)
16 0·615 
(0·406–
0·798)
7839 0·861 
(0·854–
0·868)
10 0·385 
(0·202–
0·594)
8867 0·974 
(0·970–
0·977)
4·65 mm 17 0·654 
(0·443–
0·828)
7456 0·819 
(0·811–
0·827)
Fourth 
quartile
18/9115 14·0% 0·49 
(0·30–
0·79)
0·969 
(0·947–
0·991)
17 0·944 
(0·727–
0·999)
7948 0·872 
(0·865–
0·879)
12 0·667 
(0·410–
0·867)
8914 0·978 
(0·975–
0·981)
5·75 mm 17 0·944 
(0·727–
0·999)
8194 0·899 
(0·893–
0·905)
n=number. RR=relative risk. EC=endometrial cancer. ET=endometrial thickness.
Table 5: Performance characteristics of endometrial thickness as a screening tool for endometrial cancer by quartile risk groups
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for the detection of endometrial cancer or AEH, which 
were in the range of 80–85% depending upon the target 
population and screening criteria applied. As expected, 
the optimum cutoﬀ  in asymptomatic women of 
4·45 mm is similar but lower than the 5 mm cutoﬀ 
reported for symptomatic women.26 
Of note, our report shows that 26 women (19·5%) who 
developed endometrial cancer within a year of their scan 
on UKCTOCS had an endometrial thickness of less than 
5 mm. In a theoretical model, based on the estimate that 
15% of endometrial cancers occur in women without 
vaginal bleeding, Smith-Bindman and colleagues27 
calculated the risk of endometrial cancer to be 6·7% for 
an endometrial thickness greater than 11 mm.27 This ﬁ ts 
satisfactorily with 5·9% risk of endometrial cancer in our 
cohort where 96 (72·2%) of 133 women were 
asymptomatic at an endometrial cutoﬀ  of 10 mm.
Although the data show that TVS can detect endometrial 
cancer before symptoms are detected in a high proportion 
of postmenopausal women, there are a range of issues 
that need to be addressed before population screening for 
endometrial cancer can be proposed. One important 
issue, which is not addressed in our analysis, is the eﬀ ect 
of endometrial screening on survival or mortality from 
the disease. However, the answer to this question will be 
extremely diﬃ  cult to establish even for a test with 
100% sensitivity. If we assume an incidence of 60 per 
100 000 per year and 30% mortality at 5-year follow-up, a 
randomised controlled trial would need 500 000 participants 
to document a 50% reduction in mortality. Since a trial on 
this scale is almost certainly not feasible, decisions about 
whether or not to screen for endometrial cancer will have 
to be made on the basis of surrogate measures of eﬃ  cacy. 
Two important considerations are the overall burden of 
population screening and the consequences of false-
positive results. We explored the possibility of reducing 
the overall burden of screening by focusing on a group of 
the population identiﬁ ed as being at higher risk on the 
basis of epidemiological criteria. Our logistic regression 
model that used epidemiological variables of the use of 
the oral contraceptive pill, age at menarche, number of 
pregnancies, weight, age, and history of cancer was able 
to separate the population into quartile groups at diﬀ erent 
levels of risk. With this approach, the highest risk quartile 
included almost 40% of endometrial cancer or AEH cases. 
In this group, an endometrial thickness cutoﬀ  at 6·75 mm 
achieved a sensitivity of 84·3% and a speciﬁ city of 89·9%. 
This would reduce the burden of screening to 25% of the 
population with detection of about 40% of the cases.
The strengths of our study include the large size of our 
cohort, prospective data collection with standardised 
measurement of endometrial thickness as part of the 
trial protocol, systematic follow-up, and information on 
epidemiological variables. Consistent with earlier reports 
of the correlation of endometrial thickness and HRT,28 
the median endometrial thickness in users of HRT in the 
control group was 3·6 mm versus 2·7 mm in non-users. 
Median endometrial thickness was also signiﬁ cantly 
greater in those with a history of breast cancer when 
compared with women with no history. This probably 
relates to the use of tamoxifen, which is known to be 
associated both with increased endometrial thickness 
(range 4·9–11·7 mm) in postmenopausal women29–34 
and increased risk of endometrial cancer (rates of 
0·3% vs 0·06% in women on placebo).35 We were, 
however, unable to conﬁ rm a recently reported correlation 
between ovarian volume and the risk of endometrial 
cancer of AEH reported by the PLCO trialists.36
One of the limitations of our study was that 
endometrial cancer screening was not an interventional 
endpoint in the UKCTOCS. Guidelines were provided 
based upon current practice in the UK, but the ﬁ nal 
decision was at the clinician’s discretion. The lack of 
systematic protocol-driven intervention on the basis of 
endometrial thickness meant that we could not assess 
the data by stage of endometrial cancer. Detailed data on 
the variety of procedures done was not collected, but 
this is unlikely to alter the performance characteristics 
of endometrial thickness.
A further limitation of our study is the accuracy of 
the reports of postmenopausal bleeding. Although 
sonographers were instructed to ask about and record 
symptoms of postmenopausal bleeding, we do not 
know if these data were recorded accurately. Therefore, 
there might be bias in the recording of these data for 
women who had an endometrial thickness above the 
level that triggered clinical referral (>5 mm).
There was a diﬀ erence in median endometrial thickness 
measurements in healthy women across the 13 centres. 
There are no previous data on variation in thickness 
measurements across diﬀ erent sonographers. Our 
ﬁ ndings accord with the only study we are aware of that 
included 48 postmenopausal women who were scanned 
by two examiners. In this cohort, the mean interobserver 
diﬀ erence for the same woman was 0·2 mm (SD 1·9).37 
Our variation is probably multifactorial. In addition to 
slight variations in the scanning techniques for 
measuring endometrial thickness in 36 731 individuals 
across 13 centres, it is also probably related to variations 
in the demographics such as body-mass index of patients 
between centres. It highlights the need to have training 
and quality assurance measures in place if ultrasound 
were to be used as a screen for endometrial cancer.
The CIs around parameter estimates were wide 
because of low numbers of endometrial cancers despite 
the large overall number of participants. Some key 
variables that could aﬀ ect risk of endometrial cancer, 
such as smoking,38 diabetes, and hypertension,39 could 
not be used in model building because the main focus of 
the recruitment questionnaire was on risk factors for 
ovarian cancer. Variables were collected on follow-up 
and a greater percentage of women with endometrial 
cancer reported a history or diagnosis of diabetes (nine 
[10·2%] of 88) compared with those without endometrial 
Articles
www.thelancet.com/oncology   Vol 12   January 2011 47
cancer (1429 [5·0%] of 28 801; data not shown). 
Incorporation of these factors and family history of 
endometrial cancer might have substantially improved 
the value of the high-risk score and should be assessed 
in future studies. Furthermore, although there was an 
association with weight, we could not conﬁ rm the link 
between the risk of endometrial cancer and body-mass 
index.40 A paucity of detailed information on type of HRT 
and duration of use at scan also reduced our ability to do 
further subanalyses.
False-positive results on TVS screening for endometrial 
cancer will require a form of endometrial sampling that, 
although not a major procedure, will generate anxiety, 
inconvenience, and cost. There are of course 
complications as well as costs of hysteroscopy that would 
need to be assessed carefully in a risk-beneﬁ t analysis if 
screening for endometrial cancer with TVS was to be 
introduced. We do not have data on complications of 
hysteroscopy available for this dataset. Another important 
consideration for future studies of endometrial cancer 
screening is acceptability of the screening strategy.
A cutoﬀ  at 5 mm or greater would result in 58 diagnostic 
procedures for each case of endometrial cancer detected. 
Although the number of false positives can be reduced 
substantially by increasing the cutoﬀ , this results in a 
corresponding fall in sensitivity. For a cutoﬀ  of 10 mm or 
more, sensitivity fell from 81% to 56% with the number 
of investigative procedures decreasing from 58 to 17. Of 
note, hysteroscopy—the investigation used to follow-up 
an abnormal endometrial cancer screen result—is of low 
morbidity and cost and often done as an outpatient 
procedure. The consequence of false-positive endometrial 
cancer screening ﬁ ndings is probably substantially less 
than in ovarian cancer where the consequence is 
abdominal surgery by laparoscopy or laparotomy. 
A targeted screening approach might help reduce the 
overall number of false-positive ﬁ ndings while 
maintaining a high sensitivity. We are exploring the 
possibility of further reﬁ ning risk stratiﬁ cation by 
incorporating sex-steroid hormone proﬁ ling.
Whether ovarian cancer screening will save lives is 
currently unclear and whether the primary screen should 
be with TVS or a serum biomarker is debated. 
Nevertheless, the potential for integrating endometrial 
cancer with ovarian cancer screening will be clearer once 
UKCTOCS has reported. The extra cost of incorporating 
endometrial cancer screening within the scope of an 
ovarian cancer screening trial could be marginal and add 
beneﬁ t to the screening strategy if properly modelled.
Our report is to our knowledge the ﬁ rst large-scale 
report of the performance characteristics of TVS in 
endometrial cancer screening (panel). It forms the basis 
for further studies and is not intended to answer all the 
questions that arise. In particular, issues of early 
detection, morbidity, acceptability, and health economics 
of intervening on the basis of endometrial thickness will 
need to be the subject of future studies. Any comment on 
the likely beneﬁ t of detection of endometrial cancer by 
ultrasound screening would be conjecture. We have 
limited ourselves to reporting and discussing the 
performance characteristics.
The rising incidence of endometrial cancer and the 
diﬃ  culty of doing a randomised controlled trial large 
enough to specify mortality as an endpoint, suggests that 
the decision to introduce screening for all or a subgroup 
of asymptomatic women will rest on surrogate criteria 
such as the performance characteristics described in our 
report and future studies of acceptability, health 
economics, and risk stratiﬁ cation. We do not advocate 
population screening for endometrial cancer until further 
data are available from these studies.
Contributors
IJJ, AGM, MB, SC, and UM contributed to the study design, analysis 
and interpretation of the data, and drafting and revision of the report. 
IJ, UM, and AGM did the search of published work. IJ, MB, and AGM 
prepared the ﬁ gures and tables. IJ, MB, and AGM did the statistical 
analysis. NS and RM contributed to the conﬁ rmation of the endometrial 
cancer diagnoses and the interpretation of the data. SC contributed to 
the interpretation of the data. All authors critically revised the report and 
approved the ﬁ nal version. IJ is the guarantor.
Conﬂ icts of interest
IJ has a consultancy arrangement with Becton Dickinson relating to 
tumour markers and ovarian cancer. UM and IJ has a ﬁ nancial interest 
through UCL Business and Abcodia Ltd in the third party exploitation of 
clinical trials biobanks, which have been developed through the research 
at UCL. All other authors declared no conﬂ icts of interest.
Acknowledgments
The trial was core funded by the UK Medical Research Council, Cancer 
Research UK, and the UK Department of Health with additional support 
from the Eve Appeal, Special Trustees of Bart’s and the London, and 
Special Trustees of UCLH. A substantial portion of this work was done 
at UCLH/UCL within the “women’s health theme” of the NIHR 
Panel: Research in context
Systematic review
A systematic review of ovarian cancer screening41 was published by the NHS Centre for 
Reviews and Dissemination before submission of the grant proposal to the UK Medical 
Research Council for United Kingdom Collaborative Trial of Ovarian Cancer Screening. No 
systematic review of endometrial cancer screening was done.
A detailed review of published work of endometrial cancer screening in an asymptomatic 
population was done as part of our analysis. We searched PubMed in February, 2010, with 
the terms “endometrial cancer“, “screening“, “endometrial thickness“, and 
“asymptomatic“. Our search was limited to papers in English. The largest study13 involved 
the TVS screening of 1926 postmenopausal women in the general population. One case of 
endometrial cancer and four cases of atypical hyperplasia were detected. Other studies14–16 
have included smaller populations making it impossible to assess the sensitivity of 
screening or to achieve conﬁ dent estimates of speciﬁ city or positive predictive value.
Interpretation
Our study provides to our knowledge the only large-scale data on the performance 
characteristics of TVS in endometrial cancer screening, and provides evidence that 
ultrasonography can detect endometrial cancer in asymptomatic women with 
80–90% sensitivity and similar levels of speciﬁ city. Our ﬁ ndings provide the basis for 
further studies to assess the acceptability, health economics, and risk stratiﬁ cation. 
Clinicians faced with ultrasound data on endometrial thickness from scans done in various 
disorders aside from vaginal bleeding will now have data to inform their daily practice.
Articles
48 www.thelancet.com/oncology   Vol 12   January 2011
UCLH/UCL Comprehensive Biomedical Research Centre supported by 
the Department of Health. We thank the women throughout the UK 
who are participating in the trial and to the entire medical, nursing, and 
administrative staﬀ  who work on the UKCTOCS.
References
1 Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial 
cancer incidence trends in Europe: underlying determinants and 
prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 
14: 1132–42.
2 Cancer research UK. Uterus (womb) cancer—UK incidence statistics. 
http://info.cancerresearchuk.org/cancerstats/types/uterus/incidence/ 
(accessed Oct 5, 2009).
3 Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197–209.
4 Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial 
cancer incidence trends in Europe: underlying determinants and 
prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 
14: 1132–42.
5 Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers 
of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–18.
6 Lynch HT, Lynch JF. Lynch syndrome: history and current status. 
Dis Markers 2004; 20: 181–98.
7 Smith RA, Cokkinides V, Brawley OW. Cancer screening in the 
United States, 2009: a review of current American Cancer Society 
guidelines and issues in cancer screening. CA Cancer J Clin 2009; 
59: 27–41.
8 Smith RA, Cokkinides V, Eyre HJ. American Cancer Society 
guidelines for the early detection of cancer, 2006. 
CA Cancer J Clin 2006; 56: 11–25.
9 Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing 
populations: the challenges ahead. Lancet 2009; 374: 1196–208.
10 Cancer research UK. Uterus (womb) cancer survival statistics. http://
info.cancerresearchuk.org/cancerstats/types/uterus/survival/ 
(accessed Oct 5, 2009).
11 Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in 
the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening 
trial: ﬁ ndings from the initial screen of a randomized trial. 
Am J Obstet Gynecol 2005; 193: 1630–39.
12 Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and 
speciﬁ city of multimodal and ultrasound screening for ovarian 
cancer, and stage distribution of detected cancers: results of the 
prevalence screen of the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS). Lancet Oncol 2009; 10: 327–40.
13 Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value 
of ultrasonographic screening for endometrial disease in 
postmenopausal women without symptoms. 
Am J Obstet Gynecol 2001; 184: 70–75.
14 Karlsson B, Granberg S, Wikland M, et al. Transvaginal 
ultrasonography of the endometrium in women with 
postmenopausal bleeding—a Nordic multicenter study. 
Am J Obstet Gynecol 1995; 172: 1488–94.
15 Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace 
dilation and curettage? A longitudinal evaluation of postmenopausal 
bleeding and transvaginal sonographic measurement of the 
endometrium as predictors of endometrial cancer. 
Am J Obstet Gynecol 2003; 188: 401–08.
16 Tsuda H, Nakamura H, Inoue T, Kawamura N, Adachi K, 
Bandera CA. Transvaginal ultrasonography of the endometrium in 
postmenopausal Japanese women. Gynecol Obstet Invest 2005; 
60: 218–23.
17 Menon U, Gentry-Maharaj A, Ryan A, et al. Recruitment to 
multicentre trials—lessons from UKCTOCS: descriptive study. 
BMJ 2008; 337: a2079.
18 Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial 
carcinoma in women with a biopsy diagnosis of atypical endometrial 
hyperplasia: a Gynecologic Oncology Group study. 
Cancer 2006; 106: 812–19.
19 Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the 
diagnosis of atypical endometrial hyperplasia: a Gynecologic 
Oncology Group study. Cancer 2006; 106: 804–11.
20 Zaino RJ. Endometrial hyperplasia: is it time for a quantum leap to a 
new classiﬁ cation? Int J Gynecol Pathol 2000; 19: 314–21.
21 Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial 
hyperplasia. A long-term study of “untreated” hyperplasia in 
170 patients. Cancer 1985; 56: 403–12.
22 Ferenczy A, Gelfand M. The biologic signiﬁ cance of cytologic atypia 
in progestogen-treated endometrial hyperplasia. 
Am J Obstet Gynecol 1989; 160: 126–31.
23 Sherman AI, Brown S. The precursors of endometrial carcinoma. 
Am J Obstet Gynecol 1979; 135: 947–56.
24 Wentz WB. Progestin therapy in endometrial hyperplasia. 
Gynecol Oncol 1974; 2: 362–67.
25 Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of 
endometrial carcinoma during 20-year follow-up among women with 
endometrial hyperplasia. J Clin Oncol 28: 788–92.
26 Eitan R, Saenz CC, Venkatraman ES, et al. Pilot study prospectively 
evaluating the use of the measurement of preoperative sonographic 
endometrial thickness in postmenopausal patients with endometrial 
cancer. Menopause 2005; 12: 27–30.
27 Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? 
When endometrial thickness should prompt biopsy in 
postmenopausal women without vaginal bleeding. 
Ultrasound Obstet Gynecol 2004; 24: 558–65.
28 Sit AS, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal 
ultrasound measurement of endometrial thickness as a biomarker for 
estrogen exposure. Cancer Epidemiol Biomarkers Prev 2004; 
13: 1459–65.
29 Ozsener S, Ozaran A, Itil I, Dikmen Y. Endometrial pathology of 104 
postmenopausal breast cancer patients treated with tamoxifen. 
Eur J Gynaecol Oncol 1998; 19: 580–83.
30 Kedar RP, Bourne TH, Powles TJ, et al. Eﬀ ects of tamoxifen on uterus 
and ovaries of postmenopausal women in a randomised breast cancer 
prevention trial. Lancet 1994; 343: 1318–21.
31 Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. 
Investigation of endometrial abnormalities in asymptomatic women 
treated with tamoxifen and an evaluation of the role of endometrial 
screening. J Clin Oncol 1999; 17: 2050–54.
32 Bertelli G, Venturini M, Del Mastro L, et al. Tamoxifen and the 
endometrium: ﬁ ndings of pelvic ultrasound examination and 
endometrial biopsy in asymptomatic breast cancer patients. 
Breast Cancer Res Treat 1998; 47: 41–46.
33 Cecchini S, Ciatto S, Bonardi R, et al. Screening by ultrasonography 
for endometrial carcinoma in postmenopausal breast cancer patients 
under adjuvant tamoxifen. Gynecol Oncol 1996; 60: 409–11.
34 Gerber B, Krause A, Muller H, et al. Eﬀ ects of adjuvant tamoxifen on 
the endometrium in postmenopausal women with breast cancer: a 
prospective long-term study using transvaginal ultrasound. 
J Clin Oncol 2000; 18: 3464–70.
35 Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the 
prevention of breast cancer: current status of the National Surgical 
Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 
97: 1652–62.
36 Sherman ME, Lacey JV, Buys SS, et al. Ovarian volume: determinants 
and associations with cancer among postmenopausal women. 
Cancer Epidemiol Biomarkers Prev 2006; 15: 1550–54.
37 Epstein E, Valentin L. Intraobserver and interobserver reproducibility 
of ultrasound measurements of endometrial thickness in 
postmenopausal women. Ultrasound Obstet Gynecol 2002; 20: 486–91.
38 Viswanathan AN, Feskanich D, De Vivo I, et al. Smoking and the risk 
of endometrial cancer: results from the Nurses’ Health Study. 
Int J Cancer 2005; 114: 996–1001.
39 Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, 
Baron JA. Body size in diﬀ erent periods of life, diabetes mellitus, 
hypertension, and risk of postmenopausal endometrial cancer 
(Sweden). Cancer Causes Control 2000; 11: 185–92.
40 Jonsson F, Wolk A, Pedersen NL, et al. Obesity and 
hormone-dependent tumors: cohort and co-twin control studies based 
on the Swedish Twin Registry. Int J Cancer 2003; 106: 594–99.
41 Bell R, Petticrew M, Sheldon T. The performance of screening tests 
for ovarian cancer: results of a systematic review. 
Br J Obstet Gynaecol 1998; 105: 1136–47.
